They are complementary, not competitive — most serious recovery protocols run both. BPC-157 is the local-healing specialist; TB-500 is the systemic-migration specialist. If you have to pick one, pick BPC-157 for targeted tissue injuries and TB-500 for full-body wear.
| BPC-157 | TB-500 | |
|---|---|---|
| Class | Gastric pentadecapeptide (15 amino acids) | Synthetic peptide fragment of thymosin beta-4 |
| Half-life | Oral form ~4 hours; subcutaneous estimated 4–6 hours | Approximately 2 hours (peptide); biological effect lasts longer |
| Typical dose | 200–500 mcg per injection, 1–2x daily | 2–5 mg (2000–5000 mcg) per injection, 1–2x weekly loading, then maintenance |
| Category | Healing / tissue repair | Healing / tissue repair |
| FDA status | Not FDA approved. Research use only in the US. Removed from FDA 503A bulks list in 2023. | Not FDA approved. Research use only in the US. |
| Storage | Lyophilized: room temp (stable, short term) or refrigerated. | Lyophilized stable at room temp. |
Both are research peptides with strong animal-model evidence for soft-tissue healing, both are unapproved for human use in the US, and both are commonly stacked together in injury-recovery protocols.
Pick BPC-157 for a specific injury — tendon, ligament, localized muscle strain, GI inflammation — where the pathology sits in one place. BPC-157's effect is strongest around the injection site and on gastric tissue regardless of injection site.
Pick TB-500 when the problem is systemic or distributed — generalized soft-tissue wear, overuse syndromes, post-surgical whole-body recovery. TB-500's action on cell migration and VEGF is systemic; it reaches every tissue rather than acting locally.
Yes — BPC-157 + TB-500 is the single most common healing stack. They address different mechanisms (local tissue-repair modulation vs systemic cell migration) and are widely run together for weeks at a time. See the full BPC-157 + TB-500 stack guide for cadence and dosing notes.
They stack → See our full BPC-157 + TB-500 stack guide for cadence and side-effect notes.
Peptide Protocol schedules doses, calculates reconstitution, and logs side effects for both — on iPhone, free to download.
See the app →BPC-157 acts locally around the injection site and on gastric tissue; TB-500 acts systemically via G-actin binding and angiogenesis. Different mechanisms, different scopes, which is why they pair rather than compete.
Yes — BPC-157 + TB-500 is the single most common healing stack. They address different mechanisms (local tissue-repair modulation vs systemic cell migration) and are widely run together for weeks at a time. See the full BPC-157 + TB-500 stack guide for cadence and dosing notes.
They are complementary, not competitive — most serious recovery protocols run both. BPC-157 is the local-healing specialist; TB-500 is the systemic-migration specialist. If you have to pick one, pick BPC-157 for targeted tissue injuries and TB-500 for full-body wear.
Pick BPC-157 for a specific injury — tendon, ligament, localized muscle strain, GI inflammation — where the pathology sits in one place. BPC-157's effect is strongest around the injection site and on gastric tissue regardless of injection site.
Pick TB-500 when the problem is systemic or distributed — generalized soft-tissue wear, overuse syndromes, post-surgical whole-body recovery. TB-500's action on cell migration and VEGF is systemic; it reaches every tissue rather than acting locally.
BPC-157: Not FDA approved. Research use only in the US. Removed from FDA 503A bulks list in 2023. — TB-500: Not FDA approved. Research use only in the US.
Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.